Please Wait
Applying Filters...
menu
    • menu
    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Namodenoson

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Can-Fite: FDA Approves Use of Namodenoson in Pancreatic Cancer
    Can-Fite: FDA Approves Use of Namodenoson in Pancreatic Cancer

    18 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2025/03/18/3044514/0/en/Can-Fite-FDA-Approved-Compassionate-Use-Treatment-with-Namodenoson-in-a-Pancreatic-Cancer-Patient.html

    GLOBENEWSWIRE
    18 Mar 2025
    Share Share
    Can-Fite Publishes Namodenoson Benefits In Liver Cancer
    Can-Fite Publishes Namodenoson Benefits In Liver Cancer

    03 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2025/03/03/3035375/0/en/Can-Fite-Innovative-Publication-Namodenoson-in-Liver-Cancer-Treatment-Alongside-with-Cardiac-Liver-and-Neurological-Benefits.html

    GLOBENEWSWIRE
    03 Mar 2025
    Share Share
    Can-Fite’s Namodenoson Clears Decompensated Liver Cirrhosis
    Can-Fite’s Namodenoson Clears Decompensated Liver Cirrhosis

    18 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/18/3027671/0/en/Disappearance-of-Decompensated-Liver-Cirrhosis-Episodes-After-Treatment-with-Can-Fite-s-Namodenoson.html

    GLOBENEWSWIRE
    18 Feb 2025
    Share Share
    ASCO Recognizes Can-Fite’s Namodenoson Liver Protective Effect
    ASCO Recognizes Can-Fite’s Namodenoson Liver Protective Effect

    30 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/30/3002592/0/en/Recognition-of-the-American-Society-of-Clinical-Oncology-ASCO-of-the-Liver-Protective-Effect-of-Can-Fite-s-anti-Cancer-Drug-Namodenoson.html

    GLOBENEWSWIRE
    30 Dec 2024
    Share Share
    8-Year Survival with Cure for Liver Cancer with Namodenoson
    8-Year Survival with Cure for Liver Cancer with Namodenoson

    04 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/04/2991347/0/en/8-Years-Survival-with-Complete-Cure-for-a-Patient-with-Advanced-Liver-Cancer-Being-Treated-with-Can-Fite-s-Namodenoson-Drug.html

    GLOBENEWSWIRE
    04 Dec 2024
    Share Share
    Patient Improvement Reported With Namodenoson In Liver Cirrhosis
    Patient Improvement Reported With Namodenoson In Liver Cirrhosis

    01 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/01/2906564/0/en/Improvement-in-Patient-with-Decompensated-Liver-Cirrhosis-Upon-Treatment-with-Namodenoson.html

    GLOBENEWSWIRE
    01 Jul 2024
    Share Share